These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Induction of clusterin by AKT--role in cytoprotection against docetaxel in prostate tumor cells. Zhong B; Sallman DA; Gilvary DL; Pernazza D; Sahakian E; Fritz D; Cheng JQ; Trougakos I; Wei S; Djeu JY Mol Cancer Ther; 2010 Jun; 9(6):1831-41. PubMed ID: 20501799 [TBL] [Abstract][Full Text] [Related]
4. MicroRNA-195 regulates docetaxel resistance by targeting clusterin in prostate cancer. Ma X; Zou L; Li X; Chen Z; Lin Q; Wu X Biomed Pharmacother; 2018 Mar; 99():445-450. PubMed ID: 29665645 [TBL] [Abstract][Full Text] [Related]
5. Clusterin knockdown using the antisense oligonucleotide OGX-011 re-sensitizes docetaxel-refractory prostate cancer PC-3 cells to chemotherapy. Sowery RD; Hadaschik BA; So AI; Zoubeidi A; Fazli L; Hurtado-Coll A; Gleave ME BJU Int; 2008 Aug; 102(3):389-97. PubMed ID: 18336596 [TBL] [Abstract][Full Text] [Related]
6. Possible involvement of CCT5, RGS3, and YKT6 genes up-regulated in p53-mutated tumors in resistance to docetaxel in human breast cancers. Ooe A; Kato K; Noguchi S Breast Cancer Res Treat; 2007 Mar; 101(3):305-15. PubMed ID: 16821082 [TBL] [Abstract][Full Text] [Related]
7. miRNA-34a is associated with docetaxel resistance in human breast cancer cells. Kastl L; Brown I; Schofield AC Breast Cancer Res Treat; 2012 Jan; 131(2):445-54. PubMed ID: 21399894 [TBL] [Abstract][Full Text] [Related]
8. Methylation-mediated repression of GADD45alpha in prostate cancer and its role as a potential therapeutic target. Ramachandran K; Gopisetty G; Gordian E; Navarro L; Hader C; Reis IM; Schulz WA; Singal R Cancer Res; 2009 Feb; 69(4):1527-35. PubMed ID: 19190346 [TBL] [Abstract][Full Text] [Related]
9. The establishment of two paclitaxel-resistant prostate cancer cell lines and the mechanisms of paclitaxel resistance with two cell lines. Takeda M; Mizokami A; Mamiya K; Li YQ; Zhang J; Keller ET; Namiki M Prostate; 2007 Jun; 67(9):955-67. PubMed ID: 17440963 [TBL] [Abstract][Full Text] [Related]
10. Targeting megalin to enhance delivery of anti-clusterin small-interfering RNA nanomedicine to chemo-treated breast cancer. Xue HY; Wong HL Eur J Pharm Biopharm; 2012 May; 81(1):24-32. PubMed ID: 22369881 [TBL] [Abstract][Full Text] [Related]
11. A phase I study of OGX-011, a 2'-methoxyethyl phosphorothioate antisense to clusterin, in combination with docetaxel in patients with advanced cancer. Chi KN; Siu LL; Hirte H; Hotte SJ; Knox J; Kollmansberger C; Gleave M; Guns E; Powers J; Walsh W; Tu D; Eisenhauer E Clin Cancer Res; 2008 Feb; 14(3):833-9. PubMed ID: 18245546 [TBL] [Abstract][Full Text] [Related]
12. Docetaxel associated pathways in cisplatin resistant head and neck squamous cell carcinoma: a pilot study. Yoo GH; Lin HS; Iskander AJ; Piechocki MP; Oliver J; Kewson D; Lonardo F; Tainsky MA; Kim HR; Kim H; Ensley JF Laryngoscope; 2005 Nov; 115(11):1938-46. PubMed ID: 16319602 [TBL] [Abstract][Full Text] [Related]
13. STAT5 contributes to interferon resistance of melanoma cells. Wellbrock C; Weisser C; Hassel JC; Fischer P; Becker J; Vetter CS; Behrmann I; Kortylewski M; Heinrich PC; Schartl M Curr Biol; 2005 Sep; 15(18):1629-39. PubMed ID: 16169484 [TBL] [Abstract][Full Text] [Related]
14. RPN2 gene confers docetaxel resistance in breast cancer. Honma K; Iwao-Koizumi K; Takeshita F; Yamamoto Y; Yoshida T; Nishio K; Nagahara S; Kato K; Ochiya T Nat Med; 2008 Sep; 14(9):939-48. PubMed ID: 18724378 [TBL] [Abstract][Full Text] [Related]
15. Emerging targets to monitor and overcome docetaxel resistance in castration resistant prostate cancer (review). Magadoux L; Isambert N; Plenchette S; Jeannin JF; Laurens V Int J Oncol; 2014 Sep; 45(3):919-28. PubMed ID: 24969394 [TBL] [Abstract][Full Text] [Related]
16. Clusterin confers paclitaxel resistance in cervical cancer. Park DC; Yeo SG; Shin EY; Mok SC; Kim DH Gynecol Oncol; 2006 Dec; 103(3):996-1000. PubMed ID: 16890274 [TBL] [Abstract][Full Text] [Related]
17. The mechanism of DAB2IP in chemoresistance of prostate cancer cells. Wu K; Xie D; Zou Y; Zhang T; Pong RC; Xiao G; Fazli L; Gleave M; He D; Boothman DA; Hsieh JT Clin Cancer Res; 2013 Sep; 19(17):4740-9. PubMed ID: 23838317 [TBL] [Abstract][Full Text] [Related]
18. The use of LC-MS to identify differentially expressed proteins in docetaxel-resistant prostate cancer cell lines. O'Connell K; Prencipe M; O'Neill A; Corcoran C; Rani S; Henry M; Dowling P; Meleady P; O'Driscoll L; Watson W; O'Connor R Proteomics; 2012 Jul; 12(13):2115-26. PubMed ID: 22623417 [TBL] [Abstract][Full Text] [Related]
19. Docetaxel induced gene expression patterns in head and neck squamous cell carcinoma using cDNA microarray and PowerBlot. Yoo GH; Piechocki MP; Ensley JF; Nguyen T; Oliver J; Meng H; Kewson D; Shibuya TY; Lonardo F; Tainsky MA Clin Cancer Res; 2002 Dec; 8(12):3910-21. PubMed ID: 12473607 [TBL] [Abstract][Full Text] [Related]
20. Phosphatidylinositol 3'-kinase activation leads to multidrug resistance protein-1 expression and subsequent chemoresistance in advanced prostate cancer cells. Lee JT; Steelman LS; McCubrey JA Cancer Res; 2004 Nov; 64(22):8397-404. PubMed ID: 15548710 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]